CorMedix Inc. (CRMD)
CorMedix (CRMD) Surpasses Q1 Earnings and Revenue Estimates
CorMedix (CRMD) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to loss of $0.25 per share a year ago.
CorMedix: A Fair-Priced Biotech Company With A Bright Future
CorMedix Inc.'s DefenCath, FDA-approved in Q4 2023, effectively prevents catheter-related bloodstream infections in hemodialysis patients, showing 71% efficacy compared to competitors. Despite recent profitability and strong market potential, the stock price has increased post-FDA approval, making it appropriately priced for its risk level. Key risks include adoption speed, supply chain scalability, and regulatory changes; maintaining relationships with major dialysis operators is crucial.
CorMedix Inc. (CRMD) Q4 2024 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD ) Q4 2024 Earnings Conference Call March 25, 2025 8:30 AM ET Company Participants Dan Ferry - Managing Director, LifeSci Advisors Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Erin Mistry - Executive Vice President and Chief Commercial Officer Liz Hurlburt - Executive Vice President, Chief Clinical Strategy and Operations Officer Conference Call Participants Roanna Ruiz - Leerink Partners Jason Butler - Citizens JMP Anish Nikhanj - RBC Capital Markets Jeevan Larson - Truist Securities John Todaro - Needham & Company Operator Good day and welcome to the CorMedix Inc. Fourth Quarter and Full Year 2024 Financial Results Conference Call. All participants will be in listen-only mode.
CorMedix (CRMD) Q4 Earnings and Revenues Beat Estimates
CorMedix (CRMD) came out with quarterly earnings of $0.22 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to loss of $0.26 per share a year ago.
CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
CorMedix Inc. CRMD will release its fourth-quarter financial results, before the opening bell, on Tuesday, March 25.
CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates
CRMD reports $31 million in preliminary sales from its sole marketed product in Q4, surpassing its previous guidance of breaking even by 2024.
Is CorMedix (CRMD) Stock Outpacing Its Medical Peers This Year?
Here is how CorMedix (CRMD) and ResMed (RMD) have performed compared to their sector so far this year.
CorMedix (CRMD) Upgraded to Strong Buy: What Does It Mean for the Stock?
CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Momentum Stocks to Buy for November 8th
CRMD, FFIC and SPPJY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 8, 2024.
Wall Street Analysts See a 52.15% Upside in CorMedix (CRMD): Can the Stock Really Move This High?
The consensus price target hints at a 52.2% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CorMedix Inc. (CRMD) Q3 2024 Earnings Call Transcript
CorMedix Inc. (NASDAQ:CRMD ) Q3 2024 Earnings Call October 30, 2024 8:30 AM ET Company Participants Dan Ferry - Investor Relations Joe Todisco - Chief Executive Officer Matt David - Executive Vice President and Chief Financial Officer Beth Zelnick Kaufman - Executive Vice President and Chief Legal Officer Liz Hulburt - Executive Vice President and Chief Clinical Strategy and Operations Officer Erin Mistry - Executive Vice President and Chief Commercial Officer Conference Call Participants Jason Butler - Citizens JMP Gregory Renza - RBC Capital Brandon Folkes - Rodman & Renshaw Les Sulewski - Truist Securities Serge Belanger - Needham & Company Operator Good day and welcome to the CorMedix Inc. Third Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.
CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates
CorMedix (CRMD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.17 per share a year ago.
